BriaCell Therapeutics (BCT) Stock Price, News & Analysis

Company Overview

BriaCell Therapeutics Corp. is a clinical stage immuno-oncology company that is developing an entirely new class of targeted immunotherapies to transform cancer care. Bria-IMT(TM), BriaCell's lead candidate, was awarded Fast Track status by FDA and is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC). MBC is breast cancer that has spread to other tissues. Bria-IMT(TM) is a targeted cell-based immunotherapy. Additionally, BriaCell is developing, Bria-OTS(TM), a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical study initially targeting breast cancer, with extension to prostate cancer, and other cancers.

Key Stats

• Today's Range: C$5.42 to C$5.51
• 50-Day Range: C$5.02 to C$6.33
• 52-Week Range: C$4.95 to C$52.90
• Volume: 2,415 shs
• Average Volume: 25,077 shs
• Market Capitalization: C$39.80 million
• P/E Ratio: N/A
• Dividend Yield: 13.70%
• Price Target: N/A
• Consensus Rating: N/A

BCT Stock Analysis - Frequently Asked Questions

How have BCT shares performed this year?

BriaCell Therapeutics' stock was trading at C$9.80 at the start of the year. Since then, BCT stock has decreased by 44.0% and is now trading at C$5.49.

When did BriaCell Therapeutics' stock split?

BriaCell Therapeutics's stock reverse split on the morning of Sunday, August 24th 2025.The 1-10 reverse split was announced on Sunday, August 24th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Sunday, August 24th 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

How do I buy shares of BriaCell Therapeutics?

Shares of BCT stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: TSE:BCT
• CIK: N/A
• Web: www.briacell.com
• Phone: 604-921-1810
• Fax: N/A
• Employees: 16
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): C($14.42)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -C$2.37 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -221.75%
• Return on Assets: -122.71%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.10
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: C$10.69 per share
• Price / Book: 0.51

Miscellaneous

• Outstanding Shares: 7,250,000
• Free Float: N/A
• Market Cap: C$39.80 million
• Optionable: Not Optionable
• Beta: 1.95